
Based on the discovery of a novel pathogenetic mechanism involving p75NTR receptor, authors demonstrated that p75NTR receptor inhibitors, alone or in association with TrkA receptor activators, reduce inflammatory cytokine production and prospect their use for anti-inflammatory treatment of chronic inflammatory diseases of auto-inflammatory or autoimmune origin.